ViaNautis Bio has recently been featured in multiple articles in Drug Discovery World.
Cell and gene therapies – looking forward
Our Chief Business Officer, Sam Barker, is featured in Drug Discovery World, discussing the promise and challenges of cell and gene therapies. Sam shares how targeting disease at the genetic level can transform treatment and highlights the importance of advanced delivery methods.
The article spotlights ViaNautis’s polyNaut® nanovesicles (PNVs), which overcome key barriers of traditional approaches.
Read more in the Winter edition of Drug Discovery World (pages 14–16).
JPM 2026: Less talk and more action
Our CEO, Adi Hoess, shares valuable insights from the J.P. Morgan Healthcare Conference in this article. Adi highlights emerging trends that are shaping the industry for 2026, including growing investor interest in immunology and inflammation (I&I) and central nervous system (CNS) disorders.
Good vibrations’ at London Life Science Week bode well for 2026
In this article, our CEO Adi Hoess discusses the evolving life sciences sector at London Life Sciences Week (LLSW), Europe’s premier industry event. The article covers exciting new developments from LLSW and examines the future of life science innovation, with a spotlight on the transformational power of ViaNautis’s polyNaut® nanovesicles (PNVs) to redefine genetic drug delivery.